SCHEMBL1618540

SCHEMBL1618540

CC(CC(C)(N)N)C(C)(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20846969 0.81 CYP1A2 (0.37)
SCHEMBL20847030 0.81 CYP1A2 (0.37)
SCHEMBL5050689 0.73
SCHEMBL10580520 0.73
SCHEMBL671991 0.69
SCHEMBL21761164 0.69
SCHEMBL3870346 0.69
SCHEMBL18161135 0.69
SCHEMBL23960246 0.68
SCHEMBL12829332 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101583606-B Compounds and methods for inhibiting the interaction of BCL proteins with binding partners INFINITY DISCOVERY INC 2015-04-08 CN disclosed
CN-101528716-B Compounds and methods for inhibiting the interaction of BCL proteins with binding partners INFINITY DISCOVERY INC 2013-03-27 CN disclosed
US-20110213145-A1 Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners INFINITY DISCOVERY, INC. (US) 2011-09-01 US disclosed
US-7928244-B2 Isoxazolidine small molecules; cancer, hyperproliferation disorders; blocking antiapoptotic function INFINITY DISCOVERY, INC. (US) 2011-04-19 US disclosed
EP-2064192-A2 COMPOUNDS AND METHODS FOR INHIBITING THE INTERACTION OF BCL PROTEINS WITH BINDING PARTNERS Infinity Discovery, Inc. (US) 2009-06-03 EP disclosed
WO-2008024337-A2 COMPOUNDS AND METHODS FOR INHIBITING THE INTERACTION OF BCL PROTEINS WITH BINDING PARTNERS INFINITY DISCOVERY, INC. (US) 2008-02-28 WO disclosed